CA Medical

CA Medical

California Medical News - including research, biotech, medical services and related

CA Medical - Page 3

CA Medical
California Medical News - including research, biotech, medical services and related

California IVF Fertility Doctor Welcomes Fairfield, Roseville, and Sacramento Area Western Health Advantage Members Who Need Help Getting Pregnant

DAVIS, Calif. -- California IVF: Davis Fertility Center, Inc. proudly announces a new contract with NorthBay Healthcare, a plan administrator for Western Health Advantage insurance. This contract expands infertility treatment options for NorthBay Healthcare members as well as members of other Western Health Advantage medical groups.

Fertility Patients Can Now Use One Screening for Multiple Types of Genetic Diseases Before Pregnancy

DAVIS, Calif. -- California IVF: Davis Fertility Center, Inc., working in conjunction with Gene Security Network leads the field in bringing a new test to patients that combines the detection of single-gene genetic disorders with a 24 chromosome screening.

ContinuLink Health Technologies, a Leader in Web-based Home Care Software Responds to Regulatory Change with Rapid Fire Solution

ATLANTA, Ga. -- ContinuLink, a leader in Web-based home care software understands the needs of their users. Within four days of a new CMS Regulation regarding PECOS, ContinuLink users were automatically having their physicians PECOS eligibility checked though our system. ContinuLink believes they were the first system in the country to have integrated real-time PECOS support.

Small, Smart, Stealth Nanoparticles Seek-and-Destroy Metastatic Cancers, as Epeius Biotechnologies Advances its Intellectual Property Estate with Additional U.S. Patents

SAN MARINO, Calif. -- Epeius Biotechnologies Corporation, an emerging leader in the field of targeted genetic medicine, received a notice of allowance from the USPTO for another crucial patent covering its leading tumor-targeted gene delivery platform. The issuance of this high-value patent protection for targeting metastatic disease follows on the heels of two major patent issuances.

MMDI Named Among 'Top 50 Companies to Watch' in the Medical Device Industry by Medical Device and Diagnostic Industry Magazine (MD+DI)

MINNEAPOLIS, Minn. -- Minnesota Medical Development, Inc. (MMDI) today announced that it has been named as one of the 'Top 50 Companies to Watch' in the medical device industry by Medical Device and Diagnostic Industry (MD+DI) magazine. MMDI was chosen because of its ability to achieve success and also for its ability to manufacture products that have the potential to revolutionize care practices.

Affinity Healthcare LLC Adds Neurology Specialty

BUFFALO GROVE, Ill. -- Affinity Healthcare LLC, a multi-specialty medical group practice with northwest Chicago suburban offices located in Arlington Heights and Buffalo Grove announces the addition of a Neurology specialist to its cadre of 34 physicians. Dr. Daniel B. Cacioppo, MD will treat patients by appointment at the Affinity Healthcare LLC office located at 1450 Busch Parkway, Buffalo Grove, IL 60089.

Advanced Phase I and Phase II Studies of Targeted Gene Delivery Confirm That Rexin-G Impacts Survival in Chemotherapy-resistant Bone and Soft...

SAN MARINO, Calif. -- Epeius Biotechnologies Corporation today announces the results of the clinical trial entitled 'Advanced Phase I/II Evaluation of Tumor-Targeted Gene Delivery: Intravenous Rexin-G as Stand Alone Therapy for Chemotherapy-resistant Bone and Soft Tissue Sarcoma' at the ASCO Annual Meeting on June 8, 2010. The presentation will be discussed by Dr. Kristen N. Ganjoo, Stanford University Medical Center, Palo Alto CA.

Tumor-targeted Rexin-G Prolongs Survival in Gemcitabine-resistant Metastatic Pancreas Cancer in Advanced Phase I and II Studies (ASCO 2010)

SAN MARINO, Calif. -- Epeius Biotechnologies Corporation today announces the results of the clinical study entitled 'Phase I and II Studies of Intravenous Rexin-G as Monotherapy for Gemcitabine-resistant Metastatic Pancreas Cancer' at the ASCO Annual Meeting on June 6, 2010. The presentation will be discussed by Dr. Howard W. Bruckner, Bruckner Oncology, New York, NY.

ContinuLink Health Technologies, A Leader in Web-based Home Care Software Announces Integration with Cardiocom

ATLANTA, Ga. -- ContinuLink, a leader in Web-based home care software has announced that it has entered into a business development relationship with Cardiocom to provide a two way interface between Cardiocom's Omnivisor Pro software application and the Web-based ContinuLink application. Cardiocom is a developer, manufacturer and clinical service provider of award-winning telehealth solutions.

Epeius Biotechnologies Reports Major Clinical Advances: Noteworthy Clinical Case Studies in Cancer Gene Therapy

SAN MARINO, Calif. -- Epeius Biotechnologies Corporation, a leader in the field of targeted genetic medicine, reports the publication of three major publications in the field. The first article entitled 'Rexin-G, A Targeted Genetic Medicine for Metastatic Cancer' (Expert Opinion on Biological Therapy, May, 2010) documents the development of Rexin-G: a tumor-targeted retrovector bearing a cytocidal cyclin G1 construct; the first targeted gene therapy vector to gain FDA Fast Track designation and Orphan Drug priorities for multiple cancer indications in the USA.

Sher Institute Donating Free IVF Treatments at Upcoming Seminars – Mother's Day Donations Part of 'Giving Back' Program

LAS VEGAS, Nev. -- Sher Institute for Reproductive Medicine (SIRM) is donating free In-Vitro Fertilization (IVF) treatments at upcoming fertility education seminars on May 11 and 12, in celebration of Mother's Day on May 9, 2010. The donated treatment cycles are part of the Sher Institute 'Giving Back' Program.

Topcon Introduces EyeRoute Mobile, First iPhone Application for Ophthalmic Image Management

PARAMUS, N.J. -- Topcon Medical Systems announced today that the mobile version of its successful EyeRoute(R) Image Management Suite is now available as a dedicated iPhone application from the Apple(R) iTunes store in North America. First presented in October 2009 at the American Academy of Ophthalmology Meeting in San Francisco, EyeRoute Mobile sets the stage for connectivity on the go.

Eularis Updates Reports That Help Pharmaceutical Companies Do More for Real Growth Than Simply Downsizing

LONDON, U.K. -- The pharmaceutical industry is facing unprecedented challenges on many fronts - a slew of patient expiries, a lack of blockbusters in the pipeline to replace the patent expiries, decreasing growth in many major markets, generic competition, constantly changing regulatory and competitive environment rendering old tools for analysis obsolete, increased pressure on CEOs to deliver shareholder growth resulting in budget cuts, downsizing, and less than optimal results.

Dr. Michael Sundine Joins Board of Renaissance Surgical Arts at Newport Harbor

COSTA MESA, Calif. /California Newswire/ -- Renaissance Surgical Arts at Newport Harbor, a new cutting edge outpatient surgical facility located within the Pacific Medical...

FDA Fast Track Designation for the Treatment of Pancreatic Cancer Given to Rexin-G®

SAN MARINO, Calif. /California Newswire/ -- Epeius Biotechnologies announced this week that its lead product, Rexin-G, has been granted Fast Track designation by the...

Rexin-G® Nano Particles Target Metastatic Cancers

SAN MARINO, Calif. /California Newswire/ -- Epeius Biotechnologies' Rexin-G is the world's smallest hero. Imagine if you will, a tiny particle that can travel...

Rexin-G Controls Tumor Growth and Improves Survival in Chemotherapy-Resistant Sarcoma and Osteosarcoma

SAN MARINO, Calif. /California Newswire/ -- Epeius Biotechnologies (www.epeiusbiotech.com) today announced the results of two related studies using Rexin-G, a tumor-targeted anti-cancer agent designed...

STAT Medical Consulting Works with Medicare to Get Calif. Physicians Paid

LOS ANGELES, Calif. /California Newswire/ -- In today's economy, more than ever, every dollar counts. That's why STAT Medical Consulting, Inc. announces that they...

Obama Supports Gang Violence with White House Policies, Says Pastor Craig X Rubin

LOS ANGELES, Calif. /California Newswire/ -- Pastor Rubin of The Family Church takes donations for medical marijuana at his Beverly Hills Green Cross located...

Cutting Edge Orange County Surgery Center to Bring a New Standard of Care to Area Patients

COSTA MESA, Calif. /California Newswire/ -- Renaissance Surgical Arts at Newport Harbor announced today it is entering its final phase of construction and near...

Beginners Luck, or Creative Artists of the First Rank? Epeius Bio Launches Rexin-G eBook Tutorial

SAN MARINO, Calif. /California Newswire/ -- Epeius Biotechnologies announces the launch of its new informative website, containing an award-winning video and an interactive e-book...

Obama is Powerless Over DEA Says L.A. Mayoral Candidate Craig Rubin

LOS ANGELES, Calif. /California Newswire/ -- The pro-medical marijuana candidate said, "While the DEA is raiding local marijuana facilities against the wishes of President...

Rexin-G® Shrinks Metastatic Tumors and Triples Survival Time in Chemotherapy-Resistant Pancreatic Cancer

SAN MARINO, Calif. /California Newswire/ -- Epeius Biotechnologies (epeiusbiotech.com) announced the results of a U.S. Phase I/II study evaluating the safety and efficacy of...

Epeius Biotech Awarded Patents in Europe for Targeted Genetic Anti-Cancer Medicine

SAN MARINO, Calif. -- Epeius Biotechnologies Corporation, a leader in tumor-targeted gene delivery systems, has received two additional European patents for the platform targeting...

Rexin-G Controls Tumor Growth and Improves Survival in Chemotherapy-Resistant Soft Tissue Sarcoma and Osteosarcoma

SAN MARINO, Calif. -- Epeius Biotechnologies announced today the results of Phase I/II and II studies of Rexin-G in chemotherapy-resistant metastatic soft tissue...

Epeius Rexin-G Returns to The Big Apple: Clinical Trials for Pancreatic Cancer and Breast Cancer Open in Manhattan

SAN MARINO, Calif. -- Epeius Biotechnologies Corporation announced today the expansion of clinical trials using intravenous Rexin-G for pancreatic cancer and breast cancer in...

SELECT TRIAL used Selenomethionine Instead of High-Selenium Yeast, SelenoExcell(R), says Cypress Systems

FRESNO, Calif. -- Cypress Systems, Inc, a Fresno CA based biotechnology company, emphasizes that the SELECT TRIAL results - that were announced yesterday -...

Epeius Biotech Reveals a New Generation of Tools for Medical Gene Delivery

SAN MARINO, Calif. -- Epeius Biotechnologies Corporation today announced the publication of another landmark paper describing recent technological advances in medical gene delivery. The...

LifeModeler, Inc. Provides $400K Grant to Inmotion Musculoskeletal Institute

SAN CLEMENTE -- A software grant that could lead to orthopedic surgeons being able to immediately gauge the effectiveness of implanted joints has been...

Gameshastra and Sony Europe to Develop PlayStation 2 Game Featuring Traditional Indian Sports

LOS ANGELES, Calif. -- Today, Hyderabad and Los Angeles based Gameshastra Inc, announced a partnership with Sony Computer Entertainment Europe (SCEE) to build a...

Orange County Foot Surgeon Receives International Recognition

LAKE FOREST, Calif. -- Orange County foot surgeon Dr. Richard Moy is widely recognized as the developer of "virtually pain-free" bunion surgery. Normally, bunion...

CareTools Announces iChart Available on Apple App Store

WESTLAKE VILLAGE, Calif. -- CareTools Inc., an industry recognized mobile healthcare information technology leader, today announced its native digital medical record system for iPhone...

FDA Grants Rexin-G from Epeius Biotechnologies a Third Orphan Drug Designation

SAN MARINO, Calif. -- Epeius Biotechnologies Corporation today announced that Rexin-G(R) has been granted Orphan Drug Designation by the U.S. Food and Drug Administration...

Epeius Biotechnologies’ Tumor-Targeted Rexin-G Receives FDA Orphan Drug Designation for Osteosarcoma Treatment

SAN MARINO, Calif. -- Epeius Biotechnologies Corporation today announced that Rexin-G has been granted Orphan Drug Designation by the U.S. Food and Drug Administration...

Fertility Specialist, Steven A. Brody, M.D., Ph.D. to Anchor New San Diego Medical Institute

SAN DIEGO, Calif. -- Sher Institutes for Reproductive Medicine(R) (SIRM) have announced the opening of an office in La Jolla, California, with Dr. Steven...

IV Infusions of Rexin-G Demonstrates Dose-Dependent Anti-Tumor Activity Without Toxicity

SAN MARINO, Calif. -- ASCO 2008 -- Epeius Biotechnologies announced today the results of an on-going Phase I/II study of Rexin-G for metastatic...

Rexin-G Followed by Reximmune-C Induce Tumor Necrosis and Recruitment of Tumor Infiltrating Lymphocytes

SAN MARINO, Calif. -- Epeius Biotechnologies (www.epeiusbiotech.com) announced today that the results of a Phase I Feasibility Study of sequential targeted gene delivery-using Rexin-G...

Rexin-G Monotherapy Reveals Significant Biological Activity without Toxicity in Chemo-Resistant Metastatic Breast Cancer (ASCO 2008)

SAN MARINO, Calif. -- Epeius Biotechnologies announced today the promising results of an on-going United States-based Phase I/II study of Rexin-G for metastatic breast...

M2SYS Fingerprint Software Selected by Innovative Marijuana Caregiver Logistics

SANTA BARBARA, Calif. -- M2SYS Technology, an award-winning fingerprint biometrics research and development firm, announced today that it has finalized an agreement with IMCL...

ASCO 2008: Tumor-Targeted Rexin-G Demonstrates Dose-Dependent Anti-Tumor Activity without Toxicity in Metastatic Pancreatic Cancer

SAN MARINO, Calif. -- Epeius Biotechnologies announced today the results of an on-going Phase I/II study of Rexin-G for metastatic pancreatic cancer (Chawla et...

Northern California Physician Incorporates His Personal Experience Into an Individualized Treatment Approach for Optimizing Fertility

SACRAMENTO, Calif. -- 7.3 million women experience infertility each year in the U.S. alone. In fact, 1 in 5 women have difficulty conceiving as more women than ever are having their first or subsequent child after the age of 35, a contributing factor of infertility. Enter Dr. Robert Greene's forthcoming book, "PERFECT HORMONE BALANCE FOR FERTILITY: The Ultimate Guide to Getting Pregnant" (ISBN: 978-0-307-33740-5).

Interim Analysis of Phase I/II Study of Rexin-G Confirms Efficacy

SAN MARINO, Calif. -- Epeius Biotechnologies Corporation announced today that Interim Analysis of an on-going Phase I/II study of Rexin-G for pancreatic cancer confirmed Rexin-G's anti-tumor activity with no major toxicity in patients with metastatic chemotherapy-resistant pancreatic cancer. The clinical trial design includes 5 escalating doses of intravenous Rexin-G ranging from 1 x 10e11 cfu twice a week to 4 x 10e11 cfu three times a week for 4 weeks. Treatment cycles are repeated if the patient exhibits Grade 1 or less toxicity.

Cypress Systems, Inc. Launches Cancer Prevention Health Campaign

Cypress SystemsFRESNO, Calif. -- Chairman and CEO, Paul Willis stated, "Just like his previous career at a large agribusiness company, Dr. Mark E. Whitacre has risen fast at Cypress Systems, Inc, last month being named the company's chief operating officer and president of operations." Now Cypress and Whitacre are focusing their energy on an aggressive cancer prevention campaign in order to get Americans-and people around the world-to consume a special type of selenium.

Mark Whitacre, Ph.D. Promoted to COO at Cypress Systems, Inc. and a Warner Bros. Movie to be Filmed About Him

Mark E. Whitacre, Ph.D.FRESNO, Calif. -- Cypress Systems, Inc, a Fresno CA based biotechnology company, announced that it has promoted Mark E. Whitacre, Ph.D. to become the company's Chief Operating Officer (COO) and President of Operations. Dr. Whitacre joined the executive management team in December 2006 as President of Technology and Business Development for the new east coast office.

Epeius Bio Awarded U.S. Patent for Targeted Injectable Gene Delivery In Vivo

Epeius BiotechnologiesSAN MARINO, Calif. -- Epeius Biotechnologies Corporation announced today the issue of U.S. Patent No. 7,347,998 for Targeted Gene Delivery in vivo. This patent provides additional intellectual property protection for the platform of highly advanced biotechnologies embodied in the company's leading anti-cancer agent, Rexin-G.

MedSort Online Health Record System Ensures Patient Privacy and Physician Efficiency

ENCINO, Calif. -- In December 2007, MedSort.com, a premier online personal medication list management system, launched a comprehensive personal health records system - MedSort Health(TM) - which empowers consumers and patients to take control of their health records. Since January 2007, MedSort.com has been helping patients to create and manage their medication and allergy list online.

As Targeted Gene Therapy Comes of Age in Clinical Medicine, Epeius Biotechnologies Applauds Their Academic Contemporaries

SAN MARINO, Calif. -- Epeius Biotechnologies Corporation announced today their appreciation of the accomplishments of their contemporaries in 2007, a truly remarkable year in terms of biomedical research, scholarship, and gonzo journalism. It was a year in which a definitive meeting entitled "In Vivo Barriers to Gene Delivery" was held at the prestigious Cold Spring Harbor Laboratory, where Nobel laureate James Watson presides, or shall we say presided.

ASEAN News: Epeius Biotechnologies Gains Commercial Approval for Rexin-G(R), a Tumor-Targeted Gene-Based Medicine for Metastatic Cancer

SAN MARINO, Calif. -- Epeius Biotechnologies Corporation announced today that the company has received a Certificate of Product Registration for Rexin-G(R) from the Philippine Bureau of Food and Drugs (BFAD), enabling the commercialization of its lead product as a safe and effective treatment for a broad spectrum of intractable cancers.

FDA Approves the Opening of a Phase II Registration Protocol Using REXIN-G for Osteosarcoma

SAN MARINO, Calif. -- Epeius Biotechnologies Corporation announced today that the company has taken a major step toward the commercialization of its lead product with the opening of a Phase II Registration Protocol using Rexin-G for osteosarcoma in the United States. Following the accelerated approval of Rexin-G for the treatment of all solid tumors by the Bureau of Food and Drugs in the Philippines, Epeius opened a number of Phase I/II clinical trials.

San Diego Office Added by Always Best Care Senior Services

SAN DIEGO, Calif. -- Always Best Care Senior Services has expanded into the San Diego area. America's premier In-Home Care, Assisted Living Placement Service, and Personal Response Company, is proud to announce seniors in San Diego can now rely on Always Best Care Senior Services for outstanding care.

FEATURED STORIES